Lorlatinib in the management of 1st Line ALK+ NSCLC

Speciality: Neurology


Speaker:

Dr Ajay Kumar Singh | Assistant Professor, Department of Medical Oncology, Tata Memorial Hospital

Dr Vaibhav Choudhary | Consultant and HOD Medical Oncology, Wockhardt Hospital, Nagpur

Dr Vikas Talreja | Consultant Medical Oncologist, Regency Hospital, Kanpur

Dr Tapesh Bhattacharyya | Associate Consultant Clinical Oncology, Tata Medical Centre

Description:

.A warm welcome to all the medical professionals in this interesting session on the use of Lorlatinib in the management of first line ALK+ non small cell lung cancer.

Lorlatinib has emerged as a promising option in the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). Its potent inhibition of ALK and ROS1 kinases, coupled with its ability to penetrate the blood-brain barrier, makes it a valuable therapeutic choice. Clinical studies have demonstrated favorable outcomes, including high response rates and prolonged progression-free survival, highlighting its efficacy as an initial treatment option for ALK-positive NSCLC patients.

As a highly selective ALK inhibitor, Lorlatinib offers a targeted approach to tackling the underlying driver mutation in ALK-positive NSCLC. Its efficacy in both systemic and central nervous system (CNS) disease control underscores its potential as a first-line therapy, providing patients with improved outcomes and quality of life..

Therefore, get an overall knowledge on the use of Lorlatinib in the management of first line ALK+ non small cell lung cancer. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity

2.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

3.

Cancer diagnosis does not spur improvements to survivors' diets or eating habits

4.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

5.

Microplastics can cause malignant changes in lung cells


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot